CN Patent

CN1414854A — 膦酸酯化合物

Assigned to University of California San Diego UCSD · Expires 2003-04-30 · 23y expired

What this patent protects

本发明涉及膦酸酯化合物、含有它们的组合物、得到它们的方法及其用于治疗多种医学疾病，如骨质疏松和其它骨代谢疾病、癌、病毒感染等的用途。

USPTO Abstract

本发明涉及膦酸酯化合物、含有它们的组合物、得到它们的方法及其用于治疗多种医学疾病，如骨质疏松和其它骨代谢疾病、癌、病毒感染等的用途。

Drugs covered by this patent

Tembexa (BRINCIDOFOVIR) · Emergent Biodefense

Patent Metadata

Patent number: CN1414854A
Jurisdiction: CN
Classification: —
Expires: 2003-04-30
Drug substance claim: No
Drug product claim: No
Assignee: University of California San Diego UCSD
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.